Hunan Pudao Pharmaceutical Technology Co., Ltd.

Jiudian Pharmaceutical is a modern pharmaceutical enterprise integrating R&D, production, and sales, and was listed on the ChiNext Board in October 2017.
The company was registered and established in 2001, focusing on chemical drug preparations, active pharmaceutical ingredients, traditional Chinese medicine, pharmaceutical excipients, and other fields. It now has production lines for active pharmaceutical ingredients, oral solid preparations, oral liquid preparations, gel ointments, pharmaceutical excipients, and more. The production of preparations and traditional Chinese medicine is in Liuyang Economic and Technological Development Zone, the production of active pharmaceutical ingredients and excipients is in Wangcheng Economic and Technological Development Zone, and R&D and commercial sales are in Changsha High-tech Zone.
With the core philosophy of "Jiuzhuan Zhongxi, Diannuo Jiankang" and driven by R&D and technology, the company has been rated as a National Technology Center, a National High-tech Enterprise, a Postdoctoral Scientific Research Workstation, a Provincial Engineering Technology Research Center for Respiratory Drugs, a Hunan Provincial Engineering Research Center for Novel Gel Ointments, etc., and was recognized as a Hunan Provincial Little Giant Enterprise in 2018.
The company adheres to the product strategy of "high technology, new products, patented drugs," starting from generic drugs and combining imitation with innovation, and has formed its own characteristics in fields such as external patches, gastrointestinal drugs, cardiovascular and cerebrovascular drugs, anti-inflammatory and analgesic drugs, anti-allergy drugs, and tonic and sedative drugs. In particular, the R&D and production of external patches have taken a leading position in China, and in the future the company will reach an internationally advanced level in the field of transdermal drug delivery.
The company is an R&D-driven enterprise with a sound R&D system and advanced instruments and equipment. It has more than 10,000 square meters of R&D facilities and has formed a complete experimental platform from small-scale research to pilot testing to industrialization. It has established an R&D team of nearly 400 people with PhDs, master's degree holders, and overseas returnees as the backbone. The company's leading products are all independently developed, and there are nearly 100 products under research and already submitted, which will greatly enrich the company's product line. After the new drugs under research are launched, they will become flagship products among the company's existing advantageous products. The company has 4 products that have passed or are deemed to have passed consistency evaluation.
The company spends more than 8% of annual sales revenue on new product R&D and technological innovation. Stable and sustained investment in new drug R&D will continuously enhance the company's innovation driving force.